This reprogramming is driven by the induction of the STAT3 and STAT5 pathways, triggered by tumor-derived cytokines such as G-CSF and GM-CSF, which upregulate the expression of fatty acid transporter protein 2 (FATP2). The gene discussed is SLC27A2; the disease is neoplasm.